Treats urinary tract infections. ANDA 73652, held by Impax Labs Inc. Nitrofurantoin, Macrocrystalline.
As of Nov 16, 2026, ANDA 73652 (Nitrofurantoin), held by Impax Labs Inc, was first approved by FDA on Jan 28, 1993, with 15 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Nitrofurantoin Capsules USP (Macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 28, 1993 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nitrofurantoin100MG · capsule;oral | Nitrofurantoin, Macrocrystalline | Rx |
| Apr 17, 2015 | Supplement 29Labeling · Standard review | Approved | None posted |
| Apr 17, 2015 | Supplement 21Labeling | Approved | None posted |
| Oct 12, 2011 | Supplement 28Labeling | Approved | None posted |
| Apr 15, 2009 | Supplement 26Labeling | Approved | None posted |
| Jan 16, 2008 | Supplement 24Labeling | Approved | None posted |
| Jan 16, 2008 | Supplement 23Labeling | Approved | None posted |
| Jul 29, 2002 | Supplement 10Manufacturing | Approved | None posted |
| Sep 12, 2001 | Supplement 8Manufacturing | Approved | None posted |
| Aug 2, 2000 | Supplement 7Labeling | Approved | None posted |
| Aug 2, 2000 | Supplement 6Manufacturing | Approved | None posted |
| Nov 29, 1999 | Supplement 5Labeling | Approved | None posted |
| Sep 14, 1999 | Supplement 4Labeling | Approved | None posted |
| Feb 13, 1998 | Supplement 3Labeling | Approved | None posted |
| May 12, 1997 | Supplement 2Labeling | Approved | None posted |
| May 21, 1993 | Supplement 1Manufacturing | Approved | None posted |
| Jan 28, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters